Ultragenyx Pharmaceutical Inc. Stock
The Ultragenyx Pharmaceutical Inc. price is unchanged compared to yesterday.
With 24 Buy predictions and not a single Sell prediction Ultragenyx Pharmaceutical Inc. is an absolute favorite of our community.
With a target price of 55 € there is potential for a 176.38% increase which would mean more than doubling the current price of 19.9 € for Ultragenyx Pharmaceutical Inc..
Pros and Cons of Ultragenyx Pharmaceutical Inc. in the next few years
Pros
?
B****
?
M***** P*******
?
W********* I********* f** t** n*** y****
Cons
?
G***** c******* t* c**********
?
S********** s********
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Ultragenyx Pharmaceutical Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Ultragenyx Pharmaceutical Inc. | 0.000% | 0.505% | 6.989% | -34.967% | 18.452% | -42.151% | -78.370% |
| Ligand Pharmaceuticals | 0.550% | 10.056% | 7.650% | 114.130% | 18.675% | 200.763% | 61.741% |
| United Therapeutics | -0.200% | 0.553% | 4.538% | 95.888% | 14.837% | 135.687% | 188.647% |
| Ionis Pharmaceuticals Inc. | 1.150% | -1.696% | 2.246% | 167.478% | -6.210% | 86.866% | 85.398% |
Comments
Ultragenyx Pharmaceutical (RARE) had its price target lowered by JPMorgan Chase & Co. from $120.00 to $74.00. They now have an "overweight" rating on the stock.
Show more
Ratings data for RARE provided by MarketBeat
Ultragenyx Pharmaceutical (NASDAQ:RARE) had its price target lowered by analysts at Canaccord Genuity Group Inc. from $128.00 to $79.00. They now have a "buy" rating on the stock.
Show more
Ratings data for RARE provided by MarketBeat
Ultragenyx Pharmaceutical (NASDAQ:RARE) had its price target lowered by analysts at HC Wainwright from $60.00 to $50.00. They now have a "buy" rating on the stock.
Show more
Ratings data for RARE provided by MarketBeat
News
Why Ultragenyx Pharmaceutical Stock Is Bouncing Back Today
While Ultragenyx Pharmaceutical (NASDAQ: RARE) provided the market with disappointing news yesterday -- shares plunged more than 42% -- it appears that investors aren't completely writing off the
Why Ultragenyx Pharmaceuticals Stock Is Plummeting Today
Heading into 2026 on an inauspicious note, Ultragenyx Pharmaceuticals (NASDAQ: RARE), a pharmaceutical company specializing in treatments for rare and ultra-rare genetic diseases, announced